Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

ClinicalTrials.gov ID: NCT01727141

Public ClinicalTrials.gov record NCT01727141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.

Study identification

NCT ID
NCT01727141
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,042 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2012 (Type not available)
Primary completion
Feb 2014 (Actual)
Completion
Feb 2014 (Actual)
Last update posted
Mar 29, 2016

2012 – 2014

United States locations

U.S. sites
73
U.S. states
29
U.S. cities
63
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35205 —
Novartis Investigative Site Montgomery Alabama 36109 —
Novartis Investigative Site Mesa Arizona 85205 —
Novartis Investigative Site Phoenix Arizona 85018 —
Novartis Investigative Site Fountain Valley California 92708 —
Novartis Investigative Site Fullerton California 92835 —
Novartis Investigative Site Huntington Beach California 92647 —
Novartis Investigative Site Montclair California 91763 —
Novartis Investigative Site Orange California 92868 —
Novartis Investigative Site Orangevale California 95662 —
Novartis Investigative Site Paramount California 90723 —
Novartis Investigative Site Riverside California 92506 —
Novartis Investigative Site Roseville California 95661 —
Novartis Investigative Site Sacramento California 95817 —
Novartis Investigative Site Sacramento California 95823 —
Novartis Investigative Site Sacramento California 95825 —
Novartis Investigative Site San Diego California 92117-4946 —
Novartis Investigative Site Torrance California 90502 —
Novartis Investigative Site Wheat Ridge Colorado 80033 —
Novartis Investigative Site Waterbury Connecticut 06708 —
Novartis Investigative Site Chiefland Florida 32626 —
Novartis Investigative Site Clearwater Florida 33765 —
Novartis Investigative Site Lynn Haven Florida 32444 —
Novartis Investigative Site Savannah Georgia 31406 —
Novartis Investigative Site Meridian Idaho 83642 —
Novartis Investigative Site O'Fallon Illinois 62269 —
Novartis Investigative Site River Forest Illinois 60305 —
Novartis Investigative Site Indianapolis Indiana 46256 —
Novartis Investigative Site Columbia Maryland 21044 —
Novartis Investigative Site Waltham Massachusetts 02154 —
Novartis Investigative Site Ann Arbor Michigan 48106-0525 —
Novartis Investigative Site Edina Minnesota 55435 —
Novartis Investigative Site Fridley Minnesota 55432 —
Novartis Investigative Site Minneapolis Minnesota 55407 —
Novartis Investigative Site Rochester Minnesota 55901 —
Novartis Investigative Site Biloxi Mississippi 39531 —
Novartis Investigative Site Saint Charles Missouri 63301 —
Novartis Investigative Site St Louis Missouri 63141 —
Novartis Investigative Site Omaha Nebraska 68134 —
Novartis Investigative Site Papillion Nebraska 68046 —
Novartis Investigative Site Las Vegas Nevada 89119 —
Novartis Investigative Site Brooklyn New York 11229 —
Novartis Investigative Site Brooklyn New York 11234 —
Novartis Investigative Site Great Neck New York 11021 —
Novartis Investigative Site Hendersonville North Carolina 28739 —
Novartis Investigative Site Cincinnati Ohio 45242 —
Novartis Investigative Site Cincinnati Ohio 45245 —
Novartis Investigative Site Columbus Ohio 43213 —
Novartis Investigative Site Columbus Ohio 43215 —
Novartis Investigative Site Dublin Ohio 43016 —
Novartis Investigative Site Marion Ohio 43302 —
Novartis Investigative Site Medford Oregon 97504-8741 —
Novartis Investigative Site Pittsburgh Pennsylvania 15213 —
Novartis Investigative Site Pittsburgh Pennsylvania 15221 —
Novartis Investigative Site Pittsburgh Pennsylvania 15236 —
Novartis Investigative Site Pittsburgh Pennsylvania 15243 —
Novartis Investigative Site Tipton Pennsylvania 16684 —
Novartis Investigative Site Anderson South Carolina 29621 —
Novartis Investigative Site Greenville South Carolina 29615 —
Novartis Investigative Site Spartanburg South Carolina 29303 —
Novartis Investigative Site Union South Carolina 29379 —
Novartis Investigative Site Chattanooga Tennessee 37404 —
Novartis Investigative Site Boerne Texas 78006 —
Novartis Investigative Site Dallas Texas 75231-4307 —
Novartis Investigative Site Dallas Texas 75231 —
Novartis Investigative Site El Paso Texas 79902 —
Novartis Investigative Site San Antonio Texas 78205 —
Novartis Investigative Site South Burlington Vermont 05403 —
Novartis Investigative Site Newport News Virginia 23606 —
Novartis Investigative Site Richmond Virginia 23229 —
Novartis Investigative Site Richmond Virginia 23294 —
Novartis Investigative Site Seattle Washington — —
Novartis Investigative Site Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01727141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2016 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01727141 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →